Services

RepliGut

Human in vitro small and large intestinal tissue models exhibiting polarized monolayers encompassing cell types reflecting in vivo biology. This platform is suitable for studying many aspects of drug disposition including toxicity, metabolism, drug absorption, and efficacy.

Barrier-min

Intestinal Barrier Function

Integrity of the intestinal epithelium is crucial for the normal functioning of the lower GI tract. RepliGut maintains barrier integrity with high TEER values. Compounds can be assessed for the potential to disrupt barrier function or the barrier can be compromised with cytokines and the reestablishment of barrier function quantified.

Inflammatory-min

Inflammatory Response

Inflammation of the GI tract is the main hallmark of Inflammatory Bowel Disease. The RepliGut system is comprised of polarized intestinal cells grown on transwells. Dosing with compounds can be in the luminal or basolateral compartments and sampling for the release of inflammatory mediators can be quantified in either compartment as well.

Skull-min

GI Toxicity

GI toxicities are among the most common adverse events during Phase 1 clinical trials. RepliGut recapitulates intestinal epithelium and can be used to screen compounds for drug-induced GI toxicity early in the drug development process.

Pills-min

Intestinal Drug Disposition

RepliGut can be used to measure the uptake or efflux of compounds in a manner similar to Caco-2 cells. RepliGut is superior to Caco-2 cells because the cells are not transformed and studies can be conducted with cells derived from the different regions of the small intestine and colon. More than one donor can be tested.

Available biological endpoints

  • Transepithelial electrical resistance (TEER)
  • Permeability (Papp or % of control)
  • mRNA Expression (RT-PCR)
  • Cytotoxicity (ATP levels, membrane leakiness)
  • Protein Expression (ELISA)
  • Immunohistochemistry
  • High Content Imaging